Depression and Triple-Negative Breast Cancer Prognosis with PHQ-9 Data

322.7 KB of Excel data supports a retrospective cohort study on depression as a risk factor for poor prognosis and chemotherapy resistance in triple-negative breast cancer. The dataset combines global epidemiological metrics from GBD 2021 and NHANES 2009-2018 with single-center clinical records. It was authored by Lingfeng Tang and last updated in April 2026.

Use Cases

• Analyze correlations between PHQ-9 depression scores and chemotherapy resistance outcomes in TNBC patients.
• Model the relationship between sociodemographic index (SDI) regions and disability-adjusted life years (DALYs) for breast cancer and depression across 204 countries.
• Investigate demographic and lifestyle covariates from NHANES as potential confounders in the depression-cancer prognosis link.
• Compare age-standardized mortality rates for breast cancer and depression across different global regions.

Strengths

• Integrates two authoritative public health sources: Global Burden of Disease 2021 and U.S. NHANES 2009-2018.
• Provides multi-dimensional health metrics including DALYs, YLDs, YLLs, and mortality rates stratified by SDI.

Limitations

• Limited scope at 322.7 KB, indicating a small sample size or aggregated summary data rather than individual patient records.
• Clinical data component is from a single center, which may limit generalizability.
• Temporal coverage for NHANES ends in 2018, which may not reflect recent trends.

Provenance

Source

Global Burden of Disease 2021 study and U.S. National Health and Nutrition Examination Survey (NHANES).

Collection Method

Retrospective cohort study combining aggregated global epidemiological data with single-center clinical records.

Time Range

NHANES data from 2009 to 2018; GBD data from 2021.

Freshness

Last updated in April 2026, but underlying source data (NHANES) is from 2009-2018.

Geography

Global coverage for GBD (204 countries); U.S. national coverage for NHANES.